# OnCo record nct04586231 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04586231/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04586231", "NCT04586231" ;
  schema:name "LITESPARK-011"@en ;
  schema:alternateName "LITESPARK 011"@en, "MK-6482-011"@en, "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)"@en ;
  schema:description "In LITESPARK-011, belzutifan plus lenvatinib held advanced clear-cell kidney cancer in check for about four months longer than cabozantinib in people whose cancer had grown after immunotherapy, but at the interim look it had not been shown to help them live longer; a final survival analysis is still to come."@en ;
  schema:url <https://onco.cc/trials/nct04586231/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04586231>, <https://doi.org/10.1016/S0140-6736(26)01089-5>, <https://www.eisaimedicalinformation.com/-/media/Files/EisaiMedicalInformation/Oncology/Congress-Materials/ASCO-GU-2026/Motzer_LS011_ASCO-GU-2026_Presented.pdf> ;
  onco:status "positive" ;
  onco:tag "pipeline", "issue-98" ;
  onco:phase "3" ;
  schema:startDate "2021-02-25" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/cabozantinib/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/eisai/> ;
  onco:people <https://onco.cc/people/robert-motzer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-litespark-011-motzer-lancet-2026/> .